Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial

IMPORTANCE: There is a critical need for careful and independent validation of reported symptomatic efficacy and dopaminergic biomarker changes induced by nilotinib in Parkinson disease (PD). OBJECTIVES: To assess safety and tolerability of nilotinib in participants with moderately advanced PD. Seco...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:JAMA Neurol
Main Authors: Simuni, Tanya, Fiske, Brian, Merchant, Kalpana, Coffey, Christopher S., Klingner, Elizabeth, Caspell-Garcia, Chelsea, Lafontant, David-Erick, Matthews, Helen, Wyse, Richard K., Brundin, Patrik, Simon, David K., Schwarzschild, Michael, Weiner, David, Adams, Jamie, Venuto, Charles, Dawson, Ted M., Baker, Liana, Kostrzebski, Melissa, Ward, Tina, Rafaloff, Gary
פורמט: Artigo
שפה:Inglês
יצא לאור: American Medical Association 2020
נושאים:
Original Investigation
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7737147/
https://ncbi.nlm.nih.gov/pubmed/33315105
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2020.4725
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים